Richard Hughes | Partner, Epstein, Becker & Green, Professorial Lecturer in Law,
The George Washington University Law School

Richard Hughes, Partner, Epstein, Becker & Green, Professorial Lecturer in Law,, The George Washington University Law School

Richard Hughes IV, J.D., M.P.H. is a Partner at the Washington, D.C. health care law firm, Epstein, Becker & Green and a Professorial Lecturer in Law at the The George Washington University Law School. His practice, teaching and thought leadership focus on access to preventive health care, including vaccines, PREP for HIV and contraceptives.

Richard is the former Vice President of Public Policy at Moderna. He previously founded and led the vaccines and preventive services group at Avalere Health, a Washington healthcare consultancy. Prior to practicing law, Richard served in several health policy leadership roles. He was a gubernatorial appointee to the Arkansas State Board of Health, then Director of State Health Policy at the Association of State and Territorial Health Officials and Region Policy Executive with Merck.

Prior to joining the law faculty, Richard held an academic appointment at the Milken Institute School of Public Health. During law school at The George Washington University, he served as legal research assistant to Professor Sara Rosenbaum, renowned health law scholar and Founding Chair of the GWU Department of Health Policy. In addition to his Juris Doctor, Richard holds a Master of Public Health degree. He is a member of the District of Columbia Bar and the Bar of the Supreme Court of the United States. He is also a member of the national Delta Omega Honorary Society in Public Health

Appearances:



Pre-Congress Workshops - November 27 @ 14:00

Workshop A - Antibodies: Discovery vs Computational Design

Series of presentations followed by panel discussion

Computational design of antibodies  - Dr Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

Discovery & development of broad-spectrum antibodies for Flu, COVID & RSV - Dr Phillip Lovanti, Sr. Director of R&D, Aridis Pharmaceuticals

Machine learning models for design of antibodies - Dr Sai Pooja Mahajan, Senior Scientist, Prescient Design, Genentech

Computational and artificial intelligence-based methods for antibody development - Dr Philip Kim, Professor, Principal Investigator, Department of Molecular Genetics, University of Toronto

How are NITAGs & HTAs thinking about novel antibody products? Richard Hughes, Partner, Epstein, Becker & Green, Professorial Lecturer in Law, The George Washington University Law School

 

 

 

last published: 02/Jan/24 12:15 GMT

back to speakers